2024-514611-98-00招募中3 期
A randomized phase III trial of trastuzumab + ALpelisib +/- fulvestrant versus trastuzumab + chemotherapy in patients with PIK3CA mutated previously treated HER2+ Advanced BrEasT cancer. “ALPHABET Study”
Fundacion Grupo Espanol De Investigacion En Cancer De Mama20 个研究点 分布在 1 个国家目标入组 27 人开始时间: 2024年10月24日最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 27
- 试验地点
- 20
- 主要终点
- PFS: Time from randomization to objective disease progression based on the investigator's assessment according to the response evaluation criteria for solid tumors (RECIST) version 1.1., or death from any cause.
研究概览
简要总结
-To determine whether the PI3K inhibitor alpelisib + trastuzumab improve efficacy, as measured by PFS, compared to trastuzumab + chemotherapy of physician's choice (vinorelbine, capecitabine or eribulin) in previously treated HER2+/HR- PIK3CA mutated advanced breast cancer patients. -To determine whether the PI3K inhibitor alpelisib + trastuzumab + fulvestrant improve efficacy, as measured by PFS, compared to trastuzumab + hemotherapy of physician's choice (vinorelbine, capecitabine or eribulin) in previously treated HER2+/HR+ PIK3CA mutated advanced breast cancer patients.
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 是
入选标准
- •1.Written informed consent prior to any specific study procedures, showing patient willingness to comply with all study procedures.
- •7.Female or male patient is at least 18 years of age.
- •8.Eastern Cooperative Oncology Group (ECOG) Performance Status 0-
- •9.Patients can be either males or premenopausal/perimenopausal or postmenopausal females. In the HR+ cohort, males and females who are not post-menopausal must have been on a gonadotropin-releasing hormone (GnRH) agonist (e.g. goserelin or leuprorelin) for at least 14 days prior to starting study treatment. Premenopausal status is defined as either: • Last menstrual period occurred within the last 12 months, or • If on tamoxifen: last menstrual period occurred within the past 14 days, plasma estradiol is ≥ 10 pg/mL and follicle-stimulating hormone (FSH) ≤ 40 IU/l or in the premenopausal range, according to local laboratory definition, or • In case of therapy induced amenorrhea: plasma estradiol is ≥ 10 pg/mL and FSH ≤ 40 IU/l or in the premenopausal range, according to local laboratory definition. Postmenopausal status is defined as either: • Natural (spontaneous) amenorrhea lasting more than 12 months and either age from 49 to 59 years and/or history of vasomotor symptoms (e.g., hot flush) in the absence of other medical justification, or • Levels of plasma estradiol ≤ 20 pg/mL and follicle-stimulating hormone (FSH) ≥ 40 IU/l or in the postmenopausal range, according to local laboratory definition, or • Surgical bilateral oophorectomy. Perimenopausal status is defined as neither premenopausal nor postmenopausal.
- •13.Resolution of all acute toxic effects of prior anti-cancer therapy or surgical procedures to NCI-CTCAE version 5.0 grade ≤ 1 (except alopecia or other toxicities not considered a safety risk for the patient at investigator´s discretion).
- •14.Adequate cardiac function as defined by left ventricular ejection fraction (LVEF) of ≥ 50% measured by echocardiography or multi-gated acquisition (MUGA) scans.
- •10.Measurable disease or at least one evaluable bone lesion, lytic or mixed (lytic+blastic), which has not been previously irradiated and is assessable by computer tomography (CT)/magnetic resonance imaging (MRI) in the absence of measurable disease according to RECIST 1.1 criteria.
- •11.Life expectancy ≥ 12 weeks.
- •12.Adequate organ and marrow function defined as follows: • Absolute neutrophil count (ANC) ≥ 1,500/mm3 (1.5x109/L). • Platelets ≥ 100,000/mm3 (100x109/L). • Hemoglobin ≥ 9g/dL (90g/L). • Calcium (corrected for serum albumin) and magnesium within normal limits or ≤ grade 1 according to NCI-CTCAE version 5.0 if judged clinically not significant by the investigator. • Creatinine <1.5 x upper limit of normal (ULN) or creatinine Clearance ≥ 35 mL/min using Cockcroft-Gault formula (if creatinine is ≥1.5 ULN). • Total bilirubin < 2 x ULN (any elevated bilirubin should be asymptomatic at enrollment) except for patients with Gilbert’s syndrome who may only be included if the total bilirubin is ≤ 3.0 x ULN or direct bilirubin ≤ 1.5 x ULN. • Potassium within normal limits or corrected with supplements. • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3.0 x ULN. If patient has liver metastasis, AST and ALT ≤ 5.0 x ULN. • Fasting serum amylase ≤ 2.0 x ULN. • Fasting serum lipase ≤ ULN. • Fasting plasma glucose (FPG) ≤ 140 mg/dL (7.7 mmol/L) and glycosylated hemoglobin (HbA1c) ≤ 6.4%.
- •2.Histologically or cytologically documented locally recurrent inoperable or metastatic breast cancer with HER2+ status based on local laboratory determination, preferably on the most recent available FFPE tumor sample, and according to American Society of Clinical Oncology (ASCO)/Collegue of American Pathologists (CAP) international guidelines valid at the time of the assay. In case of discordance in HER2+ status in different biopsies, the result from the most recent biopsy will be used.
- •3.Documented HR status based on local laboratory, preferably on the most recent available FFPE tumor sample, and according to ASCO/CAP international guidelines valid at the time of the assay. In case of discordance in HR status in different biopsies, the result from the most recent biopsy will be used. HR+ will be defined as ≥1% positive cells by immunohistochemistry for Estrogen Receptor (ER) and/or Progesterone Receptor (PgR). HR- will be defined as <1% positive cells by immunohistochemistry for both ER and PgR. Considering that there are limited data on endocrine therapy benefit for cancers with 1% to 10% of cells staining ER positive, for the purpose of this study, patients with ER and PgR expression between 1 and 10% (considered to be HR low by the most recent ASCO/CAP guidelines) will be eligible for inclusion in the HR- cohort.
- •4.Patients with a PIK3CA tumor mutation at central laboratory determination on the most representative archival FFPE tumor sample (ie, a block with sufficient tumor surface and cellularity) from the primary tumor or a metastatic lesion. If the tumor analysis is not informative or inconclusive for the mutation analysis, detection of PIK3CA mutations by the central laboratory on ctDNA extracted from a blood sample will be allowed.
- •5.At least 1 prior line of anti-HER2 based therapy for metastatic breast cancer (MBC).
- •6.At least 1 prior line of trastuzumab in the metastatic setting, or in the (neo)adjuvant setting (provided the patient relapsed while on therapy or within 6 months after completing adjuvant trastuzumab).
排除标准
- •1.Have recently received study agent(s) in any of the following scenarios: • Fulvestrant within 12 months prior to the start of the study treatment (HR+ cohort only). • All the chemotherapy options, vinorelbine, capecitabine and eribulin within 12 months prior to start the study treatment. Patients that have received one or more of these chemotherapies more than 12 months prior can received them again as study therapy.
- •10.Patient has clinically significant, uncontrolled heart disease and/or recent cardiac events including any of the following: • History of angina pectoris, coronary artery bypass graft (CABG), symptomatic pericarditis or myocardial infarction within 6 months of randomization. • History of documented congestive heart failure (New York Heart Association functional classification III-IV). • Clinically significant cardiac arrhythmias, (e.g., ventricular tachycardia), complete left bundle branch block, high grade AV block (e.g. bifascicular block, Mobitz type II and third degree AV block without pacemaker in place). • Uncontrolled hypertension defined by a Systolic Blood Pressure ≥ 160 mmHg and/or Diastolic Blood Pressure (DBP) ≥ 100 mm Hg, with or without anti-hypertensive medication. Initiation or adjustment of antihypertensive medication(s) is allowed prior to screening. • Long QT syndrome, family history of idiopatic sudden death or congenital long QT syndrome, or Fridericia QT correction formula (QTcF) > 470msec.
- •11.Bleeding diathesis (i.e., disseminated intravascular coagulation [DIC], clotting factor deficiency) or long-term (> 6 months) anticoagulant therapy, other than antiplatelet therapy and low dose coumarin derivatives, provided that the International Normalised Ratio (INR) is less than 1.
- •12.History of clinically significant bowel disease including abdominal fistula, or gastrointestinal perforation.
- •13.Difficulties to swallow tablets, malabsorption syndrome disease significantly affecting gastrointestinal function, resection of the stomach or small bowel, or active inflammatory bowel disease (e.g., ulcerative diseases).
- •14.Known hypersensitivity to trastuzumab, alpelisib or fulvestrant or any of their excipients. If known hypersensitivity to either vinorelbine, capecitabine, eribulin or any of their excipients, patient will be eligible as long as the investigator’s choice avoids that drug in the control arm. If known hypersensitivity to all three cytostatics (vinorelbine, capecitabine and eribulin), the patient will not be eligible.
- •15.Active infection for hepatitis B or hepatitis C.
- •16.Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study treatment administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study.
- •17.Patients with currently documented pneumonitis/interstitial lung disease (the chest Computed Tomography [CT] scan performed at screening for the purpose of tumor assessment should be reviewed to confirm that there are no relevant pulmonary complications present).
- •18.Patient with liver disease with a Child Pugh score B or C.
- •19.Patient with a history of acute pancreatitis within 1 year of screening or past medical history of chronic pancreatitis.
- •2.Symptomatic visceral disease or any disease burden that makes the patient ineligible for experimental therapy per the investigator’s best judgment.
- •20.Patient has a history of Steven-Johnson-Syndrome (SJS), Erythema Multiforme (EM), Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) or Toxic Epidermal Necrolysis (TEN).
- •21.Patient is nursing (lactating) or is pregnant as confirmed by a positive serum human Chorionic Gonadotropin (hCG) test prior to initiating study treatment.
- •22.Patient is a woman of child-bearing potential or a partner of a woman of child-bearing potential, unless agreement to remain abstinent or use single or combined non-hormonal contraceptive methods that result in a failure rate of < 1% per year during the treatment period and for at least 7 months after the last dose of study treatment, except for patients receiving fulvestrant in which this period should be of at least 2 years. • Abstinence is only acceptable if it is in line with the preferred and usual lifestyle of the patient. • Periodic abstinence (e.g., calendar, ovulation, symptothermal, or post-ovulation methods) and withdrawal are not acceptable methods of contraception. • Examples of non-hormonal contraceptive methods with a failure rate of <1% per year include tubal ligation, male sterilization (only if he is the sole partner and have been performed at least 6 months prior to screening), and certain intrauterine devices. • Alternatively, a combination of two barrier methods (e.g., a condom and a cervical cap) is also acceptable. Barrier methods must always be supplemented with the use of a spermicide. • Male participants must not donate sperm during study and up to the time period specified above. Note: Female patients or partners of male patients are not considered of child-bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (i.e., age appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy), total hysterectomy, or bilateral tubal ligation at least 6 weeks before taking study treatment. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of child-bearing potential. If local regulations to prevent pregnancy deviate from the contraception methods listed above, local regulations apply and will be described in the Informed Consent Form (ICF).
- •3.Symptomatic central nervous system (CNS) metastases. However, patients with CNS metastases who have been adequately treated, are asymptomatic and do not require corticosteroid or anti-epileptic medication are eligible.
- •4.Presence of leptomeningeal carcinomatosis.
- •5.Other invasive malignancy (different from the current breast cancer) at the time of enrollment or previous diagnosis of a completely removed malignancy within 3 years prior to randomization except for adequately treated (including complete surgical removal) of International Federation of Gynecology and Obstetrics (FIGO) stage I grade 1 endometrial cancer, basal or squamous cell carcinoma of the skin, thyroid cancer limited to thyroid gland, in situ carcinoma of the cervix, and grade 1-2 early stage bladder cancer defined as T1 or less, without nodal involvement (N0).
- •6.Patients with an established diagnosis of diabetes mellitus type I or not controlled type II (FPG > 140 mg/dL [7.7 mmol/L] or HbA1c > 6.4%), or history of gestational diabetes (as per ACOG guidelines) or documented steroid-induced diabetes mellitus.
- •7.Prior treatment with any mTOR, AKT or PI3K inhibitor.
- •8.Patients treated within the last 7 days prior to treatment initiation with: • Drugs that are strong inducers of CYP3A
- •Drugs that are inhibitors of BCRP (Breast Cancer Resistance Protein).
- •9.Patients who received before randomization: • Any investigational agent or other anti-cancer therapy not listed below within 4 weeks prior to starting study treatment (all acute toxic effects, including peripheral neurotoxicity must be resolved to NCI-CTCAE version 5.0 grade ≤1, except toxicities not considered a safety risk for the patient at the investigator´s discretion). • Chemotherapy within a period of time that is shorter than the cycle duration used for that treatment (e.g. < 3 weeks for fluorouracil, doxorubicine, epirubicine or < 1 week for weekly chemotherapy). • Biologic therapy (e.g., antibodies, other than trastuzumab which is permitted): within 4 weeks prior to starting study treatment. • Endocrine therapy: tamoxifen or aromatase inhibitor (AI) within 2 weeks prior to starting study treatment. • Corticosteroids within 2 weeks prior to starting study treatment. Note: the following uses of corticosteroids are permitted at any time: single doses, topical applications (e.g., for rash), inhaled sprays (e.g., for obstructive airways diseases), eye drops or local injections (e.g., intra-articular). • Radiotherapy within 2 weeks prior to starting study treatment (all acute toxic effects must be resolved to NCI-CTCAE version 5.0 grade <1, except toxicities not considered a safety risk for the patient at investigator´s discretion). Patients who received prior radiotherapy to >25% of bone marrow are not eligible regardless of when it was administered. • Major surgery within 4 weeks prior to starting study treatment and/or if patient has not recovered from major side effects.
结局指标
主要结局
PFS: Time from randomization to objective disease progression based on the investigator's assessment according to the response evaluation criteria for solid tumors (RECIST) version 1.1., or death from any cause.
PFS: Time from randomization to objective disease progression based on the investigator's assessment according to the response evaluation criteria for solid tumors (RECIST) version 1.1., or death from any cause.
次要结局
- OS: time from randomization to death from any cause.
- OR: complete or partial response as best overall response based on the investigator’s assessment according to RECIST version 1.1.
- Safety and tolerability: adverse events (AEs) grades will be defined by the National Cancer Institute common terminology criteria for adverse events (NCI-CTCAE) version 5.0. AE terms will be coded according to the MedDRA dictionary.
研究者
Clinical Operations Department
Scientific
Fundacion Grupo Espanol De Investigacion En Cancer De Mama
研究点 (20)
Loading locations...
相似试验
进行中（未招募）
3 期
A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy (Astefania)2023-503568-18-00F. Hoffmann-La Roche AG377
招募中
1 期
Combination of ALpelisib and Trametinib in progressive REfractory Meningiomas2024-515836-61-00Centre Hospitalier Regional De Marseille35
已完成
3 期
Pembrolizumab with Lenvatinib versus Docetaxel for Metastatic NSCLC after Platinum Doublet Chemotherapy and Immunotherapy2022-501439-18-00Merck Sharp & Dohme LLC206
招募中
1 期
Trastuzumab Deruxtecan, and pembrolizumab in participants with Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer2023-509866-39-00Daiichi Sankyo Inc.76
招募中
2 期
Tucatinib in combination with Oral Etoposide (VP16) and Trastuzumab in Patients with metastatic HER2+ Breast cancer (TUC-TOC)2022-500743-20-00Institut Curie66